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The Notch pathway is an evolutionarily conserved signaling mech-
anism that plays essential roles both during development and in 
the maintenance of adult tissue homeostasis in metazoan (1). 
Activation of Notch receptors involves the sequential cleavage by 
ADAM10 and γ-secretase, which results in the release of the Notch 
intracellular domain (NICD). NICD translocates into the nucleus, 
where it binds RBPJK and recruits Mastermind and coactivators 
to turn on target gene expression (Figure 1A and ref. 1). The physi-
ological outcome is highly context dependent: Notch1 can pro-
mote differentiation in some tissues while acting to maintain stem 
cell proliferation in others. Consequently, Notch1 can act either as 
a tumor suppresser or as an oncogene (2). In contrast to gain-of-
function mutations in Notch1 and their oncogenic role in T-ALL 
(3, 4), and perhaps in solid tumors, Notch1 loss-of-function muta-
tions have only been implicated in a limited number of tumors, 
such as skin (2), where Notch1 loss promotes tumor formation 
non–cell-autonomously by creating a wound-like environment 
and autonomously by enhancing progression to cancer (5, 6).
To determine whether Notch1 acts as a tumor suppressor in 
additional tissues, we combined a previously reported knockin 
line, NIP1::Cre allele (N1::Crelo; ref. 7), with a floxed Notch1 allele (8) 
to perform an unbiased survey of cell types that will gain a growth 
advantage when Notch1 is lost. We observed that mice with the 
genotype of N1::Crelo/fl had a shorter median life expectancy and 
developed vascular tumors in various organs, but most frequently 
in the liver. Our findings are in agreement with reports suggest-
ing that blockade of the Notch signaling pathway could enhance 
EC proliferation (9, 10) and suggest a link between loss of Notch1 
signaling and formation of vascular tumors. This finding raises 
concerns about Notch-targeting therapies in humans, in which 
vascular tumors may arise after chronic exposure to inhibitory 
Notch1 antibodies (11, 12), decoy ligands (such as Dll4; ref. 9), 
anti-Dll4 antibodies (9, 10, 13), dominant-negative Mastermind-
like 1 (MAML1) mimetics (14), or γ-secretase inhibitors, which are 
being considered as therapeutic interventions for cancer. More-
over, our model can facilitate biomarker identification and help 
uncover molecular mechanisms of vascular tumors.
Results
A model of sporadic Notch1 loss of heterozygosity. Ligand-mediated acti-
vation of Notch involves 2 sequential cleavage events that release 
the NICD from the cell membrane (Figure 1A). This unique activa-
tion mechanism allowed us to generate N1::Cre knockin mice (7), in 
which exons 28–31 of a Notch1 allele (N1) are replaced with cDNA 
encoding the λ-phage–derived site-specific recombinase Cre and a 
C-terminal 6Xmyc tag (6MT). Consequently, this is a null Notch1 
allele producing a Notch1-Cre6MT fusion protein that releases 
Cre6MT from the cell membrane following ligand binding and 
subsequent proteolysis (Figure 1A and ref. 7). We have previously 
reported that when N1::Cre is combined with the RosaLacZ reporter, 
the excision of the floxed stop cassette by ligand-dependent release 
of Cre indelibly labels cells that have experienced Notch1 activa-
tion. An active LacZ allele is then inherited by all their descendents, 
providing a powerful tool for lineage mapping (7).
We reasoned that a combination of N1::Cre expressed from one 
allele with a floxed Notch1 expressed from the other will produce 
mice in which the remaining functional (floxed) Notch1 allele 
would be inactivated at some frequency after every round of Notch1 
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activation by the N1::Cre protein. This will create progressive, age-
dependent Notch1 loss of heterozygosity (LOH; Figure 1B). Because 
of the low expression level (Supplemental Figure 1), the fusion 
with 6MT, and the inherently inefficient, ligand-dependent release 
of Cre from the membrane, very few cells will lose Notch1 after 
each round of Notch1 activation in this line (referred to herein as 
N1::Crelo). Cells that experience multiple rounds of Notch1 activa-
tion have a higher probability of becoming Notch1 null. Whereas loss 
of Notch1 may have no consequences on cells that only need 1 round 
of Notch1 activation and/or in which other Notch receptors can 
compensate for Notch1 loss, cells depending on Notch1 to maintain 
tissue homeostasis or promote the exit from cell cycle may begin to 
accumulate after Notch1 LOH. Their expansion could be detected 
by 1 of 3 reporter alleles knocked into the Rosa locus downstream 
of a floxed stop cassette: first, an allele containing click-beetle red 
(CBR) luciferase that permits periodic noninvasive in vivo luciferase 
imaging of tumor progression (RosaCBR; Supplemental Figure 2); 
second, an allele harboring LacZ that allows single-cell resolution 
postmortem analysis (RosaLacZ; ref. 15); third, an allele bearing 
enhanced yellow fluorescent protein (EYFP) that facilitates fluo-
rescence-activated cell sorting to purify cells that have experienced 
Cre activity (RosaEYFP; ref. 16). To control for the possible con-
tribution from the Cre protein (17) or from Notch1 heterozygos-
ity (18, 19), we compared mutant N1::Crelo/fl mice with control 
N1::Crelo/+ littermates throughout this study.
N1::Crelo/fl mice develop corneal plaques and display increased angiogenesis. 
N1::Crelo/fl pups were born at the expected Mendelian ratio and were 
indistinguishable from their littermate controls at weaning. In 
contrast, when the floxed Notch1 allele was combined with a knock-
in allele with improved expression of untagged Cre (i.e., N1::Crehi), 
a higher LOH frequency was observed, resulting in embryonic 
lethality at E10.5 due to defective angiogenic remodeling within 
the yolk sac (Supplemental Figure 1 and refs. 20, 21). Thus, the 
low frequency of Notch1 LOH in N1::Crelo/fl animals better mimics 
Notch1 LOH in human patients.
LOH in N1::Crelo/fl mice became evident when all animals devel-
oped corneal hyperplasia after 2–3 months (Figure 1C), as previ-
ously reported for mice with corneal Notch1 deletion (22). X-gal 
staining showed that the normal transparent, avascular cornea was 
replaced by a vascularized epidermis-like structure. Not all kerati-
nocytes and ECs expressed lacZ (Figure 1C), which indicates that 
Notch1 loss in a fraction of corneal epithelial cells was sufficient to 
disrupt corneal differentiation.
N1::Crelo/fl mice develop vascular tumors, predominantly in the liver. The 
design of our experiment permitted both control and mutant animals 
to activate the CBR luciferase reporter gene by removal of a floxed stop 
cassette in a Notch1 activation–dependent manner. In addition to the 
corneal phenotype and to increased angiogenesis in ears (Figure 1D), 
no other phenotypes were detected during monthly scans for elevated 
luciferase activity (see below). However, Kaplan-Meier analysis of 45 
Figure 1
N1::Cre excises floxed Notch1 after activation. (A and B) Loss of functional Notch1 is a low-frequency event, since only a small number of 
Cre6MT molecules reach the nucleus. C-terminal 6MT is omitted from the diagram for clarity. CoA, coactivator; CoR, corepressor; MAM, Mas-
termind. (C) All N1::Crelo/fl mice developed corneal plaques after 2–3 months, and this phenotype became more severe as animals aged. LacZ 
staining revealed that the transparent corneal was transformed into a skin-like structure with neoangiogenesis. Not all ECs and keratinocytes 
were labeled with lacZ. (D) N1::Crelo/fl mice showed increased angiogenesis in the ear. Scale bars: 150 μm (C); 10 mm (D).
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control and 41 mutant animals demonstrated that the mutants had 
significantly reduced life expectancy compared with their littermate 
controls (~420 versus ~600 days; P < 10–4, log-rank test; Figure 2A). To 
investigate the underlying pathology, we performed comprehensive 
necropsy analysis on 13 pairs of control and mutant animals. Post-
mortem analysis of mutant animals revealed reactive splenomegaly 
(Figure 2C), characterized by marked expansion of the interfollicular 
compartments with extramedullary hematopoiesis of granulocytic, 
Figure 2
N1::Crelo/fl mice developed vascular tumors. (A) Kaplan-Meier survival analysis of 41 mutant and 45 control animals. Animals euthanized or 
alive at the time of analysis were censored (44 control and 26 mutant). (B) Summary of the major pathological findings from a comprehensive 
analysis of 13 pairs of control and mutant animals. Some animals developed hemangiomas in multiple tissues, making the tumor count greater 
than 13. The distribution of hemangiomas in different organs is further dissected (see Supplemental Table 1). (C–F) Representative images 
of spleen (C) and liver from N1::Crelo/+ (D) and N1::Crelo/fl animals (E and F). (E) Liver from a naturally deceased animal. (F) Liver from a 
euthanized N1::Crelo/fl animal, in which the tumors were still intact and filled with blood. (G–I) H&E liver sections from N1::Crelo/+ (G) and N1::
Crelo/fl animals (H and I). See Results for details. (J–L) Immunostaining of liver tumor for PECAM (J), vWF (K), and PECAM and Ki67 (L). Inset 
in L shows the enlarged view of boxed area. Representative vascular tumors in other organs are shown in M (skin; H&E) and N (ovary; vWF). 
Scale bars: 50 μm; 10 μm (L, inset).
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erythrocytic, and megakaryotic lineages and no bias in B/T cell lin-
eages (Supplemental Figure 3), and consistent with the observed 
inflammation in the liver (Supplemental Figure 4). The presence of 
blood in the abdominal cavity (hemoperitoneum) was noted in 6 of 
7 naturally deceased animals (Figure 2B). Different from control liver 
(Figure 2D), the mutant liver from naturally deceased mutant mice 
was often pale, with many irregular reddened foci (Figure 2E). Some 
patches were almost white. Hemoperitoneum, in association with 
the irregular contour of the liver lobes, indicated that these patches 
might represent the collapse of blood-filled vascular spaces. Indeed, 
inspection of the liver in euthanized nonmoribund mutant animals 
of similar age revealed no blood in the abdominal cavity. Instead, the 
liver often contained numerous reddened, large blood-filled spaces, 
consistent with a diagnosis of a vascular tumor (Figure 2F).
Examination of H&E sections of mutant liver revealed various 
abnormalities (Supplemental Figure 4). In 11 of 13 animals, the 
normal homogenous and compact hepatic parenchyma seen in 
controls (Figure 2G) was replaced either with solid, hypercellular 
tissue composed of spindle and epithelioid cells interspaced with 
numerous vascular channels (Figure 2H) or with irregular vascular 
channels lined by cells with a scant-to-moderate eosinophilic cyto-
plasm and round-to-oval nuclei (Figure 2I). The nuclei in cells lin-
Figure 3
Imaging tumor progression. (A) MRI was used to assess tumor progression in the liver. H&E images of the liver from respective animals are also 
shown. Scale bar: 100 μm. (B) Bioluminescence imaging of live animals and freshly dissected organs at the specified ages. Shown are mean and 
SD of organ luciferase signal (105 photons/s) from at least 4 different individuals of the same genotype. Organs showing statistically significant 
differences in signal intensity are boxed in red. See Supplemental Figure 6 for images of more organs.
Downloaded on October  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43114
research article
804	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 2   February 2011
ing vascular cavities either were hyperchromatic or contained coarse 
chromatin (Figure 2I and Supplemental Figure 5). The endothelial 
origin of these cells was confirmed by strong staining with EC mark-
ers PECAM-1 (CD-31) and vWF (Figure 2, J and K). Many cells were 
also positive for the cell proliferation marker Ki67 (Figure 2L). These 
findings were consistent with a diagnosis of vascular tumor/heman-
gioma in most animals, with incipient hemangiosarcoma in a few.
Although comprehensive analysis on all 13 pairs of animals 
exposed a plethora of minor anatomic phenotypes and symptoms 
in addition to those described above (Figure 2B), the statistically 
significant finding (P = 10–5, 1-tailed Fisher exact test) was that 11 
of 13 mutant animals (84.6%) had hemangioma/vascular tumors, 
some with multiple involved organs. These included the ovary, 
testis, skin, lymph node, uterus, and colon (Figure 2, B, M, N, and 
Supplemental Table 1). Nonetheless, the liver was the primary 
site affected in 81.8% of mutant animals (9 of 11; Figure 2B and 
Supplemental Table 1), within which the tumor progression could 
be assessed with MRI (Figure 3A and Supplemental Videos 1–3). 
In contrast to mutant animals, none of the control animals devel-
oped vascular tumors (Figure 2B), even late in life (~2 years).
Incidence of vascular tumors in various organs correlates with efficiency 
of EC labeling. The high incidence rate of hemangioma in the liver 
prompted us to ask whether Notch1 activation is similar in all 
vascular (i.e., red) organs. Flow cytometry analysis of EYFP+ ECs 
from control N1::Crelo/+ animals revealed that the liver ECs had 
significantly higher EYFP labeling efficiency (Figure 4), perhaps 
reflecting higher remodeling rates. Interestingly, these differences 
mirrored tumor incidence rates (Figure 2B).
Bioluminescence imaging of tumor progression. Our attempt to moni-
tor tumor growth in mutant animals by in vivo imaging with CBR 
luciferase failed, because of the overwhelmingly strong signal from 
LOH of Notch1 in the intestine (Figure 3B and ref. 7). However, no 
lesions were found in the intestinal system, consistent with the 
redundant role for Notch2 in this niche (23). Notch2 activation 
was not detected in any EC (data not shown). To confirm that vas-
cular tumor cells experienced Cre activity, we performed ex vivo 
bioluminescence imaging on freshly dissected organs and observed 
statistically significant differences between control and mutant 
liver starting at as early as 1 month of age, long before animal 
survival was compromised (Figure 3B). Notably, bioluminescence 
increased with tumor progression (Figure 3B and Supplemental 
Figure 6). The failure to identify any other foci with significantly 
increased bioluminescence among 12 N1::Crelo/fl animals indicates 
that other tumors were unlikely to be present.
EC proliferation is a direct consequence of Notch1 loss. Histological 
analysis identified multiple LacZ-positive ECs within the mutant 
liver parenchyma; costaining of PECAM/Ki67, PECAM/EYFP, and 
EYFP/BrdU confirmed that proliferating (Ki67+ or BrdU+) cells 
were of endothelial origin, expressed the reporter, and may have 
lost functional Notch1 (Figure 2L and Figure 5A).
The analyses performed thus far suggest that Notch1 deletion 
occurred in many ECs in the N1::Crelo/fl animal. To evaluate the 
status of the Notch1 locus in liver ECs, we enriched for these cells 
by a Percoll gradient isolation (24, 25) followed by fluorescence-
activated cell sorting (FACS). CD105+CD45– proliferating liver 
ECs from N1::Crelo/flRosaEYFP/LacZ and N1::Crelo/+RosaEYFP/LacZ mice 
were collected (Figure 6A), and the DNA was purified and sub-
jected to PCR amplification in order to detect the 3 Notch1 alleles: 
a normal promoter in the N1::Crelo allele, a floxed promoter in N1fl 
allele, and a rearranged N1del allele lacking the proximal promoter 
and exon1 (Figure 6B). In all tissues isolated from N1::Crelo/fl ani-
mals, N1del was readily detected (Figure 6B, bottom). In addition, 
both the N1fl and the wild-type N1::Crelo promoters were detected 
in multiple tissues and in unsorted cells (Figure 6B, top). In con-
trast, only the intact N1::Crelo allele, but not the N1fl allele, was 
detected in purified, proliferating ECs (CD45–CD105+), regardless 
of their EYFP expression status (Figure 6A, gates c and d). This 
indicates that the vast majority (>90%; Supplemental Figure 7) 
of proliferating liver ECs have lost the functional (N1fl) allele. 
Analysis of DNA from cells sorted with the pan-EC marker CD31 
detected the N1fl allele in both CD31+EYFP+ and CD31+EYFP– ECs 
(Figure 6A, gates e and f). The presence of a functional Notch1 in 
pan-ECs but not CD105+ proliferating ECs, the exclusive BrdU 
labeling of EYFP+ ECs (but not any other linage in the liver; Fig-
ure 5A), and the presence of hyperphosphorylated retinoblastoma 
protein (Rb; Figure 5, B–E) strongly argue that Notch1 suppresses 
proliferation and vascular tumor formation cell autonomously, as 
previously reported in cultured ECs (26, 27).
Figure 4
Comparison of the RosaEYFP reporter labeling efficiency in ECs of 
different organs in N1::Crelo/+RosaEYFP/LacZ mice. (A) ECs from liver, 
kidney, spleen, heart, and lung were enriched, stained with CD45 and 
CD31, and subjected to flow cytometry analysis. Percent CD31+EYFP– 
and CD31+EYFP+ cells among CD45– cells is indicated. (B) Statistical 
analysis on 4 N1::Crelo/+RosaEYFP/LacZ mice showed that the liver had 
the highest percentage of EYFP+ ECs (about 20%, compared with less 
than 5% in other organs). *P < 0.05.
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Discussion
The Notch signaling pathway is an essential component in a com-
plex network that controls proper development and maintains tis-
sue homeostasis in the adult. The embryonic lethality associated 
with loss of Notch1 (28, 29) prevents a comprehensive evaluation of 
its role in various organs in later embryonic stages or in the adult. 
To circumvent this problem, most genetic approaches adopt trans-
genic or Cre-LoxP–based conditional loss-of-function strategies 
(30) to express or remove a gene of interest in most or all cells with-
in a population. An obvious limitation of these methods as models 
for human cancer is that they do not mimic sporadic occurrence 
of disease-causing mutations in a few tumor-initiating cells, which 
later evolve into a tumor. Moreover, transgenic approaches could 
overwhelm the immune system or disrupt homeostatic mecha-
nisms that might otherwise play significant roles in determining 
disease progression. To overcome these limitations, hormone-
controlled CreER — a fusion protein of Cre recombinase and the 
binding domain of estrogen receptor — is often used to randomly 
induce sporadic overexpression or deletion of a gene of interest. 
Such strategy has been recently used to induce the sporadic expres-
sion of a SYT-SSX2 fusion gene in multiple tissues, resulting in 
exclusively synovial sarcoma-like tumors (31).
Here we devised an alternative strategy to hormone-induced 
CreER by taking advantage of the low-frequency, activation-
dependent trans-excision of a floxed Notch1 allele in N1::Crelo/fl 
animals to investigate its role in the adult stage. We identified 
the EC population as dependent on Notch1 activity in the adult 
and defined the consequence of Notch1 loss: the development of 
vascular tumors. Unlike the skin, in which tumor promotion is 
elicited by the non–cell-autonomous consequences of a wound-
like environment (5), the tumor suppressor function of Notch1 
ECs appears to be cell autonomous. Nevertheless, although these 
tumors could be found in various organs, they were most prevalent 
in the liver. Consistent with this observation, we found that ECs 
from liver have the highest EYFP labeling efficiency, suggestive of 
higher levels of angiogenic activity and thus higher probability of 
Notch1 LOH. Alternatively, some unique features of liver ECs (32), 
as well as the specific anatomical or environmental factor(s), may 
predispose the liver to vascular tumor formation.
Our study demonstrates the utility of NIP::Cre mice in screening 
for tumor suppressor functions in vivo and indicates that NIP::Cre 
mice can serve as a general model in which to initiate sporadic can-
cer. When compared with transgenic or regular Cre-floxed–based 
strategies (30), the advantages of NIP::Cre mice are as follows: first, 
the loss or gain of mutations is sporadic, and their probability can 
be manipulated by selecting either the N1::Crelo or the N1::Crehi alleles 
to better mimic cancer initiation in human patients; second, in gain-
of-function analysis, tissues that normally do not express Notch1 
will not be forced to express it; third, in loss-of-function paradigms, 
most cells will have an active Notch1 allele during development, and 
a normal physiological niche could therefore be maintained; and 
fourth, unlike a tamoxifen-dependent pulse of gene loss, cells that 
continuously depend on Notch1 have a higher probability of LOH 
than do cells that activate Notch1 only once in their history. Con-
sidering that Notch1 is continuously required in multiple tissues 
during development and in the adult (33), especially in the gut (7, 
34) and mammary gland (35) stem cell populations, a NIP::Cre allele 
coupled with floxed alleles of tumor suppressors offers a better 
model to mimic LOH disease development in human patients.
The Notch pathway has emerged as a target to block angio-
genesis in solid tumors (9, 10, 36) and eliminate tumor-initiat-
ing cells (13), either by the administration of anti-Dll4 antibody 
Figure 5
Characterization of vascular tumor cells.  
(A) LacZ-, PECAM/EYFP-, and BrdU/
EYFP-stained liver sections. A single, 
2-hour-long pulse of BrdU labeled 
5%–10% of ECs. Inset in right panel 
shows the enlarged view of boxed area. 
Scale bars: 50 μm; 10 μm (inset). (B–E) 
Immunostaining of phospho-Rb. Phos-
pho-Rb signal was absent in areas without 
tumor (B and C); the presence of the sig-
nal (brown) is shown in D and E. Sections 
were counterstained with hematoxylin. 
The tumor identity in D and E was con-
firmed with PECAM and Ki67 costaining 
in Figure 2L (adjacent sections). Boxed 
regions in B and D are shown at higher 
magnification in C and E, respectively. 
Scale bars: 100 μm.
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(9, 10, 13) or by the overexpression and/or application of a solu-
ble Dll4 protein (9). However, here we showed that chronic reduc-
tion in Notch1 signaling could promote vascular tumor forma-
tion, and may do so in humans. Consistent with our observation, 
Yan and colleagues recently showed that chronic injection of Dll4 
antibodies into adult mice, rats, and monkeys induces vascular 
neoplasm only in rats (37). We reproduced this observation in the 
mouse using a Notch1 LOH genetic model, which indicates that 
the vascular tumors found in rats treated with Dll4 antibodies 
could be caused by a mechanism-based toxicity due solely to the 
loss of Notch1 signaling in ECs. Concomitant loss of signals from 
other Notch receptors, such as Notch4 in ECs (38) and Notch2/3 
in pericytes (39–41), may have accelerated the tumor formation 
in their model (37). Although no other types of tumors appear 
sensitive to anti-Notch1 therapy, the therapeutic window of anti-
Notch therapies in general, and anti-Notch1 therapies in particu-
lar (11), needs to be carefully reevaluated.
Methods
Mice. N1::Crelo (NIP-Cre; Jax Mice strain name Notch1tm3(cre)Rko; ref. 7), Notch1 
floxed conditional mice (Jax Mice strain name Notch1tm2Rko; ref. 8), and the 
RosaLacZ (15) and RosaEYFP (16) reporter animals have been described 
previously. N1::Crehi, an enhanced version of N1::Crelo with an increased 
amount of N1::Cre fusion protein, is described previously (21, 20) and 
in Supplemental Figure 1. RosaCBR, a Cre reporter line in which the gene 
encoding CBR luciferase is under the control of the ubiquitous Rosa26 
promoter and preceded by a floxed stop cassette, is constructed in a similar 
way as the RosaLacZ (15) and RosaEYFP (16) knockin animals (Supplemen-
tal Figure 2). All animals were housed in the mouse facility of Washington 
University, and all protocols were approved by the Animal Studies Com-
mittee of Washington University.
Immunohistochemistry. Paraffin sections were prepared with standard 
procedures from postmortem or euthanized animals. Antigens were 
retrieved by boiling at 121°C for 20 minutes in 10 mM sodium citrate buf-
fer (pH 6.0) after deparaffinization. Endogenous peroxidase activity was 
inactivated in 3% H2O2 for 15 minutes before the sections were blocked 
with blocking buffer (3% BSA, 0.1% Tween in 1× PBS) for 1 hour at room 
temperature. This was then followed by overnight incubation with dif-
ferent primary antibodies at 4°C. After 3 5-minute washes with 1× PBS, 
sections were incubated at room temperature for 1 hour with HRP-conju-
gated anti-rabbit or anti-goat secondary antibodies (Vector Labs, 1:100), 
depending on the host species of the primary antibodies. DAB reactions 
were performed following 3 5-minute washes in 1× PBS with substrate 
from Vector Labs. Sections were counterstained with hematoxylin for 
30 seconds, dehydrated, and mounted with VectaMount (Vector Labs). 
For immunofluorescence staining, 3% H2O2 treatment was omitted, and 
DyLight488- or DyLight549-conjugated secondary antibodies (Jackson 
ImmunoResearch, 1:500) were used. For frozen sections, tissues were fixed 
in 4% PFA, equilibrated with 30% sucrose in 1× PBS overnight, embedded 
in OCT compound, and cut at 8 μm. For BrdU staining, 10 μl 10 mg/ml 5-
bromo-2-deoxyuridine solution (Sigma-Aldrich) per gram body weight was 
injected intraperitoneally into animals 2 hours before sacrifice. Frozen sec-
tions were first stained with chick anti-EYFP primary antibody and Alexa 
Fluor 488–conjugated donkey anti-chick secondary antibody, followed by 
treatment with 2N HCl at 37°C for 30 minutes and BrdU staining. The fol-
lowing primary antibodies were used: rabbit anti-Ki67 (Novocastra, 1:300, 
paraffin sections), goat anti–PECAM-1 (M-20) (Santa Cruz, 1:50, paraffin 
and frozen sections), rabbit anti-vWF (AbCam, 1:800, paraffin sections), 
chick anti-GFP (Aves Lab, 1:1,000, frozen sections), rat anti-BrdU (clone 
BU1/75, Accurate Chemical, 1:200, frozen sections), and rabbit anti–phos-
pho-Rb (Ser780) (Cell Signaling, 1:100, paraffin sections).
X-gal staining. Animals were anesthetized and perfused with 2% 
paraformaldehyde plus 0.25% glutaraldehyde in 1× PBS with 2 mM MgCl2. 
Tissues were then dissected and postfixed in 4% paraformaldehyde in 1× 
PBS with 2 mM MgCl2 on ice for 1 hour, washed, equilibrated with 30% 
sucrose in 1× PBS with 2 mM MgCl2 overnight, and embedded in OCT 
compound. 8-mm frozen sections were cut and stained with X-gal stain-
ing solution as described previously (7). Tissues from postmortem animals 
were processed similarly, except for perfusion.
Purification of liver ECs and flow cytometry. Freshly dissected liver from con-
trol and mutant animals was mechanically disrupted between 2 glass slides 
and digested with collagenase IV (Sigma-Aldrich). ECs were enriched by 
Figure 6
Loss of Notch1 in ECs is associated with their 
rapid expansion. (A) Liver ECs were sorted to 
remove CD45+ cells and then separated based 
on the expression of EYFP and either CD105 
(proliferating EC marker) or CD31 (pan-EC 
marker). (B) PCR analysis confirmed the deletion 
of floxed Notch1 allele in the majority of CD45–
CD105+EYFP+ and CD45–CD105+EYFP– cells; 
in contrast, a substantial amount of floxed alleles 
was still detected in CD45–CD31+EYFP+ and 
CD45–CD31+EYFP– cells. The primers bind at 
positions illustrated in the diagram. Lanes a–f cor-
respond with gates in A. M, molecular marker.
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Percoll gradient centrifugation (25) and stained with PerCP-Cy5.5–con-
jugated anti-CD45 (BD Biosciences) and PE-conjugated anti-CD105 or 
-CD31 (BioLegend) antibodies. FACS sorting was done on a MoFlo instru-
ment (Beckman Coulter). For the comparison of EYFP labeling efficiency 
in the liver, kidney, spleen, heart, and lung, tissues were first mechanically 
disrupted and then digested with collagenase IV (Sigma-Aldrich, liver or 
kidney, 5 mg per animal), collagenase D (Roche, lung or spleen, 5 mg per 
animal), or collagenase II (Worthington, 3,000 U) supplemented with 200 
U DNase I (Roche). Single-cell suspensions from peripheral blood, thymus, 
spleen, and bone marrow were prepared and analyzed with flow cytometry 
as described previously (42). Flow cytometry analyses were performed on 
FACScan (BD Biosciences), and data were analyzed with FlowJo (Treestar). 
Fluorescence-conjugated antibodies were purchased from Biolegend.
PCR. Primers 1c (5′-TGGAAGCTACTGACTTAGTAGGGGGAAAAC-3′) 
and 2d (5′-GCAAGCATGAAGTGGTCCAGGGTGTGAGTG-3′) were used 
for the simultaneous detection of floxed and wild-type Notch1 allele and 
produced a 317-bp band for wild-type Notch1 locus and a 367-bp band for 
floxed Notch1 locus. Primers 1b (5′-TGGCCTGCCTGTCTGGAACAACAGT-
TCAGG-3′) and 2e (5′-ACCCTTGCCTCAGTTCAAACACAAGATACG-3′) 
amplified the deleted Notch1 allele with a product size about 532 bp.
Bioluminescence imaging. For bioluminescence imaging of living animals, 
mice were anesthetized with 2.5% isoflurane, injected intraperitoneally 
with 150 μg/g d-luciferin (Biosynth) in PBS, and imaged with a charge-
coupled device (CCD) camera–based bioluminescence imaging system 
(IVIS 50, Caliper; exposure time 1–60 seconds, binning 8, field of view 
12, f stop 1, open filter, anterior and posterior views). Signal was dis-
played as photons/s/cm2/sr (43). Regions of interest (ROIs) were defined 
manually around the abdomen, throat, and whole body using Living 
Image and Igor Pro Software (version 2.50), and results were analyzed 
as photon flux (photons/s). Ex vivo images were obtained immediately 
after live imaging. Animals were euthanized, and organs were quickly 
removed and imaged for 60 seconds.
MRI. All MRI experiments were performed in Washington University’s 
Biomedical MR Laboratory. Respiratory-gated, spin-echo MR images of 
mice were collected with a small-animal MR scanner based on an Oxford 
Instruments (Oxford) 4.7-tesla, 40-cm bore magnet. The magnet is equipped 
with Magnex Scientific (Oxford) actively shielded, high-performance (21 cm 
ID, ~30 G/cm, ~400 ms rise time) gradient coils and Oy International Elec-
tric Company power supplies and is interfaced with a Varian NMR Systems 
DirectDrive console. All data were collected using a Stark Contrast 2.5-cm 
birdcage-style radio frequency coil. Prior to the imaging experiments, mice 
were anesthetized with isoflurane and were maintained on isoflurane/O2 
(1%–1.25% v/v) throughout data collection. Animal core body temperature 
was maintained at 37°C ± 1°C by circulation of warm air through the bore 
of the magnet. During the imaging experiments, the respiration rates for 
all mice were regular and approximately 2 s–1. Synchronization of MR data 
collection with animal respiration was achieved with a home-built respira-
tory-gating unit (44), and all images were collected during postexpiratory 
periods. 24–30 contiguous coronal slices, ventral to dorsal, were collected 
for each mouse. Imaging parameters were as follows: excitation pulse repeti-
tion time, approximately 3 s; time to echo, 30 ms; field of view, 2.5 cm2; slice 
thickness, 1.0 mm; data matrix, 128 × 128; 4 averages.
Statistics. Kaplan-Meier survival analysis was done with SPSS. Unpaired 
2-tailed Student’s t test was performed using Excel 2008 software. 
1-tailed Fisher’s exact test was computed with Statistics Calculators 
(http://www.danielsoper.com/statcalc/calc29.aspx). A P value of 0.05 or 
less was considered significant.
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